Delavirdine
- Generic Name
- Delavirdine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N6O3S
- CAS Number
- 136817-59-9
- Unique Ingredient Identifier
- DOL5F9JD3E
- Background
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
- Indication
用于高效抗逆转录病毒疗法（HAART）的组成药物。
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 34
- Registration Number
- NCT00000891
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 300
- Registration Number
- NCT00000882
- Locations
- 🇺🇸
State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 471
- Registration Number
- NCT00000803
- Locations
- 🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 120
- Registration Number
- NCT00000810
- Locations
- 🇺🇸
Howard University Hosp., Div. of Infectious Diseases, ACTU, Washington, District of Columbia, United States
🇺🇸Stanford CRS, Stanford, California, United States
🇺🇸SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
- Conditions
- HIV Infections
- Locations
- 🇺🇸
Willow Clinic, Menlo Park, California, United States
🇺🇸Stanford Univ Med Ctr, Stanford, California, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 300
- Registration Number
- NCT00000892
- Locations
- 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸Mount Sinai Med Ctr, New York, New York, United States
🇺🇸Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.